Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial

[1]  E. Tolosa,et al.  The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II , 2021, Frontiers in Neurology.

[2]  R. Pahwa,et al.  The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review , 2021, Advances in Therapy.

[3]  J. Ferreira,et al.  Clinical Utility of Opicapone in the Management of Parkinson’s Disease: A Short Review on Emerging Data and Place in Therapy , 2021, Degenerative neurological and neuromuscular disease.

[4]  T. Müller.  Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence , 2021, Journal of experimental pharmacology.

[5]  P. Calabresi,et al.  Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities , 2020, Movement disorders : official journal of the Movement Disorder Society.

[6]  Dongfeng Liu,et al.  Levodopa/carbidopa/entacapone for the treatment of early Parkinson’s disease: a meta-analysis , 2020, Neurological Sciences.

[7]  O. Witte,et al.  Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study , 2020, Translational Neurodegeneration.

[8]  K. Chaudhuri,et al.  Should there be less emphasis on levodopa‐induced dyskinesia in Parkinson's disease? , 2019, Movement disorders : official journal of the Movement Disorder Society.

[9]  W. Poewe,et al.  Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions , 2019, European journal of neurology.

[10]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[11]  C. Sampaio,et al.  International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[12]  J. Grant,et al.  Minnesota Impulse Disorders Interview (MIDI): Validation of a structured diagnostic clinical interview for impulse control disorders in an enriched community sample , 2018, Psychiatry Research.

[13]  W. Poewe,et al.  Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial , 2017, JAMA neurology.

[14]  K. Chaudhuri,et al.  Clinically relevant cut-off values for the Parkinson's Disease Sleep Scale-2 (PDSS-2): a validation study. , 2016, Sleep medicine.

[15]  Werner Poewe,et al.  Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial , 2016, The Lancet Neurology.

[16]  Meg E. Morris,et al.  Health-Related Quality of Life in patients with Parkinson's disease—A systematic review based on the ICF model , 2016, Neuroscience & Biobehavioral Reviews.

[17]  L. Vacca,et al.  How to optimize the treatment of early stage Parkinson’s disease , 2015, Translational Neurodegeneration.

[18]  A. Falcão,et al.  Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations , 2014, European Journal of Clinical Pharmacology.

[19]  E. Hirsch,et al.  Pathogenesis of Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[20]  G. Stebbins,et al.  Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society‐unified Parkinson's disease rating scale scores , 2012, Movement disorders : official journal of the Movement Disorder Society.

[21]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[22]  Angelo Antonini,et al.  Wearing‐off scales in Parkinson's disease: Critique and recommendations , 2011, Movement disorders : official journal of the Movement Disorder Society.

[23]  Kallol Ray Chaudhuri,et al.  Parkinson's disease sleep scale—validation of the revised version PDSS‐2 , 2011, Movement disorders : official journal of the Movement Disorder Society.

[24]  J. Jankovic,et al.  Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study , 2010, Annals of neurology.

[25]  L. Kiss,et al.  Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. , 2010, Journal of medicinal chemistry.

[26]  C. Duyckaerts,et al.  The second brain and Parkinson’s disease , 2009, The European journal of neuroscience.

[27]  Paolo Barone,et al.  The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[28]  E. Tolosa,et al.  End-of-dose Wearing Off in Parkinson Disease: A 9-Question Survey Assessment , 2006, Clinical neuropharmacology.

[29]  W. Poewe,et al.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[30]  C. Olanow,et al.  Continuous dopaminergic stimulation in early and advanced Parkinson’s disease , 2004, Neurology.

[31]  C Trenkwalder,et al.  The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[32]  R. Fitzpatrick,et al.  The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease , 1995, Quality of Life Research.

[33]  E. Mohr,et al.  Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part I , 1988, Annals of neurology.

[34]  J. Bartko,et al.  Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II , 1988, Annals of neurology.

[35]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[36]  G. Block,et al.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. , 1997, European neurology.

[37]  Z. Schwab,et al.  Projection technique for evaluating surgery in Parkinson’s disease , 1969 .

[38]  W. Poewe,et al.  Clinical Interventions in Aging Dovepress Levodopa in the Treatment of Parkinson's Disease: an Old Drug Still Going Strong , 2022 .